HIV-1 proviral resistance mutations: Usefulness in clinical practice

HIV Medicine

Volumn 11, Issue 8, 2010, Pages 483-492

  Kabamba Mukadi, B ^a   Duquenne, A ^a   Henrivaux, P ^a   Musuamba, F ^a   Ruelle, J ^a   Yombi, J C ^a   Bodeus M ^a   Vandercam, B ^a   Goubau, P ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

CD4 cells; HIV 1; Mutation; Na ve patients; Provirus; Resistance

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RNA GENE; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; VIRUS MUTATION;

ADULT; AGED; AMINO ACID SEQUENCE; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; PREVALENCE; PROSPECTIVE STUDIES; PROVIRUSES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; STATISTICS, NONPARAMETRIC; VIRAL LOAD; YOUNG ADULT;

EID: 77955241467     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00814.x     Document Type: Article

References (40)

1. Boden D, Hurley A, Zhang L. HIV-1 drug resistance in newly infected individuals. JAMA 1999, 282:1135-1141.
2. Little SJ, Daar ES, D'Aquila RT. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999, 282:1142-1149.
3. Vercauteren J, Derdelinckx I, Sasse A. Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses 2008, 24:355-362.
4. Wensing AMJ, Vercauteren J, van de Vijver DA. for the SPREAD Programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008, 22:625-635.
5. Angarano G, Monno L, Appice A. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts [Letter]. AIDS 1994, 8:1013-1014.
6. Yerly S, Vora S, Rizzardi P. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001, 15:2287-2292.
7. Conlon CP, Klenerman P, Edwards A. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis 1994, 169:411-415.
8. Hecht FM, Grant RM, Petropoulos CJ. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998, 339:307-311.
9. Ippolito G, Del Poggio P, Arici C. Transmission of zidovudine-resistant HIV during a bloody fight [letter]. JAMA 1994, 272:433-434.
10. Imrie A, Beveridge A, Genn W. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine: Sydney Primary HIV Infection Study Group. J Infect Dis 1997, 175:1502-1506.
11. Veenstra J, Schuurman R, Cornelissen M. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. Clin Infect Dis 1995, 21:556-560.
12. Yerly S, Kaiser L, Race E. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999, 354:729-733.
13. Baxter JD, Mayers DL, Wentworth DN. Final results of CPCRA 046: a pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Antivir Ther 1999, 4((Suppl 1)):43.
14. Baxter JD, Mayers DL, Wentworth DN. A randomized study on antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing antiretroviral therapy. AIDS 2000, 14:F83-F93.
15. Clevenbergh P, Durant J, Halfon P. Persisting long-term benefit of antiretroviral genotypic guided treatment for HIV-infected patients failing HAART. Antivir Ther 1999, 4((Suppl 1)):42.
16. Cohen C, Hunt S, Sension M. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002, 16:579-588. for the VIRA3001 Study Team.
17. Tural C, Ruiz L, Holtzer C. Clinical utility of HIV-1 genotyping and expert advice: the Havanna trial. AIDS 2002, 16:209-2018.
18. Hirsch MS, Günthard HF, Schapiro JM. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an international AIDS society-USA panel. Clin Infect Dis 2008, 47:266-285.
19. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008, 9:65-71. and the EACS Executive Committee.
20. Grant RM, Hecht FM, Warmerdam M. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002, 288:181-198.
21. Hammer SM, Saag MS, Schechter M. Treatment for adult HIV infection, 2006 recommendations of the international AIDS society-USA panel. JAMA 2006, 296:827-843.
22. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001, 15:309-320. The Euro Guidelines Group for HIV resistance.
23. Vandamme AM, Sonnerborg A, Ait-Khaled M. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004, 9:829-848.
24. Wensing AMJ, van de Vijver DA, Angarano G. Prevalence of drug resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005, 192:958-966.
25. Descamps D, Flandre P, Calvez V. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. JAMA 2000, 283:205-211.
26. Havlir DV, Hellmann NS, Petropoulos CJ. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000, 283:229-234.
27. http://www.iasusa.org/resistance_mutations, International AIDS Society-USA Resistance Mutations Project Panel. Update of the drug resistance mutations in HIV-1. Available at, (accessed 3 February 2006
28. Riva E, Pistello M, Narciso P. Decay of HIV type 1 DNA and development of drug-resistant mutants in patients with primary HIV type 1 infection receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2001, 17:1599-1604.
29. Chew CB, Potter SJ, Wang B. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol 2005, 33:206-216.
30. Bona I, Gibellini D, Borderi M. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J Clin Virol 2007, 38:313-320.
31. Wang YM, Dyer WB, Workman C. Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART. Curr HIV Res 2007, 5:235-250.
32. Ghosn J, Pellegrin I, Goujard C. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006, 20:159-170. for the French PRIMO Cohort Study Group (ANRS CO 06)
33. Usuku S, Noguchi Y, Sakamoto M. Analysis of a long-term discrepancy in drug-targeted genes in plasma HIV-1 and PBMC HIV-DNA in the same patient. Jpn J Infect Dis 2006, 59:122-125.
34. Pabsta R, Rosenbergb YJ. Interpreting data on lymphocyte subsets in the blood of HIV patients - organ distribution, proliferation and migration kinetics are critical factors. Pathobiology 1998, 66:117-122.
35. Schnuda ND. Circulation and migration of small blood lymphocytes in the rat. I. Kinetics of lymphocyte circulation in the lymphoid organs. Am J Pathol 1978, 93:623-638.
36. Girard PM, Katlama Ch, Pialoux G. VIH 2001, Paris, Doin
37. Schmit JC, Cogniaux J, Hermans P. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis 1996, 174:962-968.
38. http://hivdb.stanford.edu/pages/algs/sierra_mutation.html, The Stanford mutation list version 6.0.3. Available at, (accessed 1 September 2009)
39. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
40. Noë A, Plum J, Verhofstede C. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrob Chemother 2005, 55:410-412.